"10.1371_journal.pone.0079260","plos one","2013-11-19T00:00:00Z","Unnop Jaisamrarn; Xavier Castellsagué; Suzanne M Garland; Paulo Naud; Johanna Palmroth; Maria Rowena Del Rosario-Raymundo; Cosette M Wheeler; Jorge Salmerón; Song-Nan Chow; Dan Apter; Julio C Teixeira; S Rachel Skinner; James Hedrick; Anne Szarewski; Barbara Romanowski; Fred Y Aoki; Tino F Schwarz; Willy A J Poppe; F Xavier Bosch; Newton S de Carvalho; Maria Julieta Germar; Klaus Peters; Jorma Paavonen; Marie-Cecile Bozonnat; Dominique Descamps; Frank Struyf; Gary O Dubin; Dominique Rosillon; Laurence Baril; HPV PATRICIA Study Group","Department of Obstetrics and Gynaecology, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand; Unit of Infections and Cancer, Cancer Epidemiology Research Program, Institut Català d’Oncologia (ICO), IDIBELL, CIBER-ESP, L’Hospitalet de Llobregat, Catalonia, Spain; Department of Microbiology and Infectious Diseases, The Royal Women's Hospital, Parkville/Department of Microbiology, The Royal Children's Hospital, Parkville/Murdoch Childrens Research Institute, Parkville/Department of Obstetrics and Gynaecology, University of Melbourne, Parkville, Victoria, Australia; Department of Gynecology & Obstetrics, Federal University of Rio Grande do Sul, UFRGS/HCPA - Hospital de Clínicas de Porto Alegre, Porto Alegre, Brazil; Central Hospital of North Carelian, Department of Obstetrics and Gynecology, Joensuu, Finland; San Pablo Colleges Medical Center, San Pablo City, Laguna, Philippines; Departments of Pathology and Obstetrics and Gynecology, University of New Mexico Health Sciences Center, Albuquerque, New Mexico, United States of America; Unidad de Investigación Epidemiológica y en Servicios de Salud, Instituto Mexicano del Seguro Social, Morelos, Mexico; Department of Obstetrics and Gynecology, College of Medicine and the Hospital, National Taiwan University, Taipei, Taiwan; Family Federation of Finland, Sexual Health Clinic, Helsinki, Finland; Departamento de Tocoginecologia da Unicamp, University of Campinas, Campinas, Sao Paulo, Brazil; Vaccines Trials Group, Telethon Institute for Child Health Research, Perth, Western Australia; Sydney University Discipline of Paediatrics and Child Health, Children’s Hospital, Westmead, Sydney, New South Wales, Australia; Kentucky Pediatric and Adult Research, Bardstown, Kentucky, United States of America; Centre for Cancer Prevention, Wolfson Institute of Preventive Medicine, Queen Mary University of London, London, United Kingdom; Division of Infectious Diseases, Department of Medicine, Faculty of Medicine and Dentistry, University of Alberta, Edmonton, Alberta, Canada; Department of Medical Microbiology, University of Manitoba, Winnipeg, Manitoba, Canada; Central Laboratory and Vaccination Centre, Stiftung Juliusspital, Academic Teaching Hospital of the University of Wuerzburg, Wuerzburg, Germany; Department of Gynaecology, University Hospital KU Leuven Gasthuisberg, Leuven, Belgium; Network on Cooperative Cancer Research, RTICC, Catalonia, Spain; Department of Gynecology and Obstetrics, Federal University of Paraná, Infectious Diseases in Gynecology and Obstetrics Sector, Curitiba, Parana, Brazil; Department of Obstetrics and Gynaecology, University of the Philippines College of Medicine, Philippine General Hospital, Manila, Philippines; Facharzt für Frauenheilkunde und Geburtshilfe, Hamburg, Germany; Department of Obstetrics and Gynaecology, University of Helsinki, Helsinki, Finland; Clinics, Paris, France; GlaxoSmithKline Vaccines, Wavre, Belgium; GlaxoSmithKline Vaccines, King of Prussia, Pennsylvania, United States of America","Wrote the manuscript: UJ XC SMG MRDRR PN J. Palmroth LB DR. Collected data for the trial and cared for the subjects: UJ XC SMG PN J. Palmroth MRDRR CMW JS S-NC DA JCT SRS JH AS BR FYA TFS WAJP FXB NSdC MJG KP J. Paavonen. Designed and/or conducted the trial and/or analyses: MCB DD FS GOD DR LB. Reviewed and commented upon a draft of the manuscript and gave final approval to submit for publication: UJ XC SMG PN J. Palmroth MRDRR CMW JS S-NC DA JCT SRS JH AS BR FYA TFS WAJP FXB NSdC MJG KP J. Paavonen MCB DD FS GOD DR LB. Had full access to all the trial data including existing analyses and final responsibility for the decision to submit for publication: UJ XC SMG MRDRR PN J. Palmroth LB DR..","The authors have the following interests: DD, GD, LB, FS and DR are paid employees of the GlaxoSmithKline group of companies, the funder of this study. DD, DR, GD, LB and FS own stocks in GlaxoSmithKline Biologicals SA, and GD receives royalties from Wyeth Vaccines. SMG owns stock in CSL Ltd. AS, MRDRR, SMG, UJ, XC have received grants/funding through their institutions to do research for GlaxoSmithKline Biologicals SA. JP has received grants/funding through their institutions to do research for GlaxoSmithKline Biologicals SA and Merck Sharp & Dohme. FXB has received, via his institutions, educational grants from GlaxoSmithKline Biologicals SA and Merck Sharp & Dohme, Sanofi Pasteur MSD; JH has received grants through his institution by Kentucky Pediatric and Adult Res. DA has received grants through his institution by VL-Medi, Väestöliitto. CMW, JCT and SRS have received grants/have grants pending from GlaxoSmithKline Biologicals SA; JS, SMG and XC have received grants/have grants pending from GlaxoSmithKline Biologicals SA and Merck Sharp & Dohme, and XC from Sanofi Pasteur MSD. SMG and SRS have received grants/have grants pending from CSL Ltd; JS has received grants from Qiagen; CMW has received reagents and equipment through the Unviersity of New Mexico for HPV genotyping from Roche Molecular Systems. MCB, SMG and TFS have received consulting fees from GlaxoSmithKline Biologicals SA; AS, XC have received consulting fees or honoraria from GlaxoSmithKline Biologicals SA and Merck Sharp & Dohme, and XC from Sanofi Pasteur MSD; MRDRR, have received honoraria from GlaxoSmithKline Biologicals SA; FYA, JCT, SMG, SRS and TFS have received payment for board membership by GlaxoSmithKline Biologicals SA; WAJP has have received payment, via his institution for board membership, consultancy and expert testimony; AS, FYA, JCT, MJG, NSC, SMG, TFS, WAJP and XC have received payment for lectures including service on speakers bureau; AS, FYA, SMG and TFS have received payment for the development of educational presentations; AS, CMW, FYA, JCT, JH, MJG, MRDRR, SMG, SRS, UJ and XC have received travel reimbursements from GlaxoSmithKline Biologicals SA. DA has received travel reimbursements from VL-Medi. FXB and XC have received travel reimbursement from Merck Sharp & Dohme, Sanofi Pasteur MSD. NSDC has received travel reimbursement from IPAMICover DTG. J Palmroth has been invited to international gynecological cancer congresses by Merck Sharp & Dohme, Sanofi Pasteur MSD and Roche who sponsored congress fees and travel costs. BR has received payment for consultancy, payment for lectures including service on speakers bureau and support for travel via her institution by B Romanowski Prof Corporation. FXB has received support for travel and honorarium for speaking at meeting organized by GlaxoSmithKline Biologicals SA, Merck Sharp & Dohme, Sanofi Pasteur MSD. There are no patents, products in development or marketed products to declare. This does not alter our adherence to all the PLOS ONE policies on sharing data and materials, as detailed online in the guide for authors. Dr. Szarewski passed away prior to the publication of the paper. The corresponding author, Unnop Jaisamrarn, has supplied the information regarding her contributions to the manuscript and her competing interests and they are correct to the best of his knowledge.","2013","11","Unnop Jaisamrarn","UJ",30,TRUE,NA,NA,NA,6,TRUE,FALSE,TRUE,11,"7;9;10;12;14;15;16;19;20;22;30",TRUE
